Navigation Links
BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Date:11/5/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York.

WHEN: Monday November 10th at 12:00pm (Eastern Time)

WHERE: New York Palace Hotel, New York.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, th
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
5. BioMS Medical to present at UBS Global Life Sciences Conference
6. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. BioMS Medical Announces Second Quarter 2008 Results
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. BioMS Medical to present at BMO Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Involution Studios , ... of a new infographic, Understanding Ebola . ... beautifully designed, easy to follow informative tool for anyone ... outbreak, symptoms and prevention. , "As the news has ... 2014 Ebola outbreak represents not only a healthcare crisis ...
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... reveal critical evidence, as well as an identity, with ... University that detects trace amounts of explosives, drugs or ... new technology also can distinguish between overlapping fingerprints left ... optical forensic methods. , A team led by R. ...
... Brazil, Sept. 23 A bill designed to,strengthen ... by,the U.S. Senate Foreign Relations Committee, is a ... the United States to promote the production,and use ... the,Brazilian Sugarcane Industry Association (UNICA)., "It shows ...
... 23 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... the Company,s pressure cycling technology ("PCT") was ... Fifth International Conference on,High Pressure Bioscience and ... San Diego, CA. The HPBB Conference was ...
Cached Biology Technology:Fingerprints provide clues to more than just identity 2New Bill to Expand Promotion of Biofuels Is a Welcome Boost for U.S.-Brazil Relations According to Brazilian Sugarcane Industry 2New Bill to Expand Promotion of Biofuels Is a Welcome Boost for U.S.-Brazil Relations According to Brazilian Sugarcane Industry 3Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending 'PCT Shredder' at the Meeting 2Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending 'PCT Shredder' at the Meeting 3Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending 'PCT Shredder' at the Meeting 4
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... REDWOOD CITY, Calif., Oct. 28 , WHAT: ... speak at the Dallas SecureWorld Expo in the Industry ... "Protecting the User-Led Aspect of Endpoint Security," Fulton will ... caused by end users. He will further examine how ...
... emerging for how important it is for pregnant women to ... day seem to have children who are less likely to ... from the Sahlgrenska Academy at the University of Gothenburg, ... Linkping University, which is conducting a population study called ABIS ...
... Olympus, a precision technology leader creating innovative opto-digital ... today announced the availability of VisiGlide 1 , its ... Terumo Corporation 2 to facilitate ERCP procedures ... of the bile and pancreatic ducts, the new 0.025 ...
Cached Biology News:DigitalPersona to Speak at Dallas SecureWorld Expo 2Vegetables can protect unborn child against diabetes 2Olympus introduces the VisiGlide, a single-use guidewire 2
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose Pale yellow solid. An N-nitroso-containing ... nitric oxide donor in pancreatic islets. ... Causes DNA alkylation and DNA strand ... ≥95% by HPLC. Soluble in H ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: